Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of January 7, 2010. The registrant is a Delaware corporation headquartered in Berkeley Heights, NJ.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on a corporate governance decision regarding dividend payments.
Material Changes
On January 7, 2010, the Board of Directors decided not to declare the quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock for the fourth quarter of 2009, which was due on February 1, 2010. This follows the Board's decision not to declare dividends for the first, second, and third quarters of 2009. Unpaid dividends are accrued.
Outlook, Risks, and Contingencies
- Governance Contingency: If the Company fails to pay an aggregate amount equal to at least six quarterly dividends (whether consecutive or not), the Board size will increase by two members.
- Voting Rights: Upon triggering the above condition, Preferred Stock holders gain the right to vote separately as a class to fill the two new Board vacancies until all accrued but unpaid dividends are paid.
- Management Commentary: The Board will continue to evaluate the payment of cash dividends on a quarterly basis.
Investor Verification Checklist
- Verify the total number of consecutive or non-consecutive quarters where dividends have been missed to assess if the six-quarter threshold for Board expansion is approaching.
- Confirm the current status of accrued but unpaid dividends on the 6% Convertible Exchangeable Preferred Stock.
- Review the Company's cash position in subsequent filings to determine the likelihood of future dividend declarations.